- Who is Carles Font and where does his interest in cosmetics come from?
I currently hold the position of Co-CEO and Chief Business Development Officer at mesoestetic®, playing a crucial role as second generation alongside my brother, Xavier Font, who holds the position of Co-CEO and Chief Legal & Compliance Officer.
My career at mesoestetic® dates back to my 16th year, during which I have held roles in various departments, including Production and Warehouse. My academic background includes a degree in Chemical Sciences obtained at the University of Barcelona, supported by a Management Development Programme (PDD) at IESE. After completing my university studies, I joined the company full time, assuming the position of Area Manager in the Commercial Department.
Currently, my focus is on leading business development at mesoestetic®, playing the role of Co-CEO together with the other members of the Operating Committee, as well as being an active part of the Board of Directors.
ommittee, as well as being active part in the Board of directors.
- Where is mesoestetic® right now after having made an investment of 10 million euros?
With this 10 million euro investment we have tripled the company's production capacity, which is enabling us to provide more and better service to our customers. At the same time, we are improving our research and development capacity.
The recent incorporation of cutting-edge laboratories positions mesoestetic® as the only entity in Spain with facilities and resources dedicated exclusively to Research, Development and Innovation (R&D&I) in disciplines such as Biotechnology, Bioengineering, Galenic and Technology Transfer. In these areas, we work synergistically to consolidate our excellence and leadership in aesthetic medicine treatments.
- What milestones is mesoestetic® experiencing in the last four months of 2023?
During the last four months of 2023, mesoestetic® has reached significant milestones that reinforce our global presence and demonstrate our commitment to innovation.
One of the most notable achievements was the opening of a new subsidiary in the United Arab Emirates, specifically in Dubai. This strategic expansion allows us to strengthen our presence in a key region and to offer our products and services to a growing market.
In addition, I am pleased to say that we have successfully completed four new launches, which represent the culmination of our ongoing commitment to research and development, providing advanced skin care solutions. Chief among them is blemiderm®, the innovative line designed to address acne imperfections, which includes both a medical treatment and a line for home use.
We have also presented the evolution of cosmelan®, our world-leading depigmentation treatment, incorporating the latest advances in depigmentation:
1. We have integrated our own patented molecule (melaphenone®), which reduces tyrosinase activity by more than 50%, thus generating a decrease in the production of melanin responsible for the spots.
2. We have incorporated a complex encapsulated with a plastic membrane that makes it possible to overcome the cutaneous barrier in depth, reaching the target and preserving the integrity of the active ingredients. This component, called cosmesome, reduces melanin synthesis by 47%.
We have also renewed our renowned mesopeel® range with eight new medical and four professional solutions, introducing multi-acid peelings with innovative formulas that include a transverse complex with regenerative action.
Finally, we have launched Genesis®, our new multi-technology equipment that offers unlimited solutions and becomes an essential tool in the aesthetic centre as it can be combined with multiple aesthetic treatments. This optimised and renewed version is designed to meet the current needs of professionals in the sector. In addition, as is traditional every year, we have introduced our limited edition Christmas sets.
These events are a reflection of mesoestetic®'s dedication to excellence and the continuous search for improvement. We are committed to continuing to offer high quality products and services that meet the needs of our customers around the world.
- What are the long-term goals of mesoestetic®?
We are a company that has been growing at double-digit rates since our foundation. In this regard, our main focus is on achieving sustainable development on a commercial, operational and global level.
In addition, we intend to continue to generate value for our community, our employees and partners and, of course, to continue working to remain at the forefront of scientific research, developing real applications in our sector which, in many sub-specialties, has already moved from aesthetic medicine to health.
- What are the areas in which mesoestetic® expects to grow the most?
We are currently immersed in the development of a new line of injectable products for the medical field, which we hope will be a revolution in the market due to its high level of innovation and differentiation with respect to other existing products on the market. In addition, the company, thanks to this desire for innovation and the generation of unique products, is working on two new patents that will help to reinforce the message of unique products and differentiating brand.
- In addition, at the same event, you highlighted that one of the main objectives for 2023 was internationalisation and in 2022 mesoestetic was present in 109 countries with some of its products and with a subsidiary in Poland and that there was a new market or point on the map to study such as the Middle East. At the hearing it was explained that Dubai was one of the locations in which mesoestetic wanted to have a presence with a subsidiary, what is the current status of this proposal?
The UAE subsidiary, specifically Dubai, is now a reality. Since last October, the subsidiary has been operational and we are confident that this milestone will mark a significant turning point in strengthening our brand position in the Middle East region in the coming years.
- To what extent have the talent of professionals and people become a key point in the growth and consolidation of mesoestetic®?
A company is built on the know-how of its human team and will only be as good as its employees. The main asset of mesoestetic® is the professionals we have at the service of the project, 220 people, almost 100 more than just 4 years ago.
- mesoestetic® has made a commitment to innovation. What results do you expect to obtain after this investment? (Better consumer perception, more market share, better positioning in the cosmetics industry, more turnover, etc...).
We have a commitment to our customers and we must improve for them, and we achieve this by researching and reinvesting in R&D&I. Our clients trust our products and treatments because they know that the results are guaranteed, and our duty is to offer them, more and more, effective and safe solutions.
On the other hand, we must bear in mind that we are in the aesthetic medicine sector and that this is a very competitive market, so it is very important to constantly work on differentiating ourselves from other brands.
We are committed to constant reinvestment in the project, in what we believe in, and we are increasingly investing part of that profit in R&D&I and in the facilities necessary to carry out business developments. A 35% growth in the last year has to be supported by a series of investments made within the company, whether in facilities, personnel, knowledge, etc.
- What are the main challenges mesoestetic® sees in the cosmetics industry?
On the one hand, we face the challenge of digitalisation and rapid technological progress, crucial aspects in the evolution of cosmetic and medical-aesthetic products, as well as in the processing and management of data for business decision-making. At mesoestetic®, we have consolidated our position as a pioneer in developing a molecule using advanced tools such as artificial intelligence and computational design. It is imperative that we maintain this cutting edge to continually lead in our industry.
On the other hand, we are committed to the sustainability not only of our products, but of the entire value chain. We approach this challenge with the awareness that it appeals directly to us and is a legacy for future generations.
Sustainability decision-making presents considerable complexity, as in several aspects of our sector there are still no viable alternatives. Nevertheless, we pursue constant progress in all possible areas, researching and keeping on our radar possible alternatives that are truly more energy and environmentally efficient.
- What do you see as the future of the cosmetics industry and the future of mesoestetic?
Nobody knows the future! But we do begin to glimpse trends and consumption patterns that are here to stay.
From the perspective of brands in the industry, ensuring the visible efficacy of our products has become increasingly important. Consumers, influenced by rising price trends and more democratised access to scientific and referenced information, are expected to increasingly value efficacy over comfort. At mesoestetic®, we are fully aligned with this premise. We recognise that, when purchasing a product or undergoing a treatment, customers have an expectation of tangible results. This principle has been consistently emphasised by my father, Joan Carles Font, founder and current president of the company. His perspective is clear: "People buy with their time, the time they have invested by earning the money they put into a product. Our customers give us their trust, we have a duty to respond to them with a product that works".
In line with the above, we observe a growing demand for proven ingredients. Despite the lack of novelty associated with established ingredients, recognised ingredients - such as vitamin C or retinol - continue to attract consumer attention. As a company, we are committed to elevating both the efficacy and sustainability of our products, ensuring that launches do not fall into the "boring" category.
On the other hand, time is precious and beauty consumers are beginning to look for effective and convenient treatments that minimise the time spent on day-to-day skincare.
Naturalness is another major consideration. Consumers are already looking for more natural, sustained and, if necessary, reversible ageing, rather than opting for major changes that are too abrupt. Healthy-looking, balanced and even-toned skin will continue to be a primary goal for consumers of all ages.
Finally, companies in the industry will need to leverage technology to optimise the personalisation of our products and treatments. Even the most educated skincare shoppers can feel overwhelmed when looking for a new product to add to their routine. We will be able to apply AI, DNA analysis and other smart technologies to help consumers address their skin concerns in a smart and effective way.
We will need to coordinate this personalisation with different life stages. Combine predictive modelling with a data-driven approach to better understand how skin changes with age, hormones and environmental factors. Consider future strategies to group consumers according to their needs in a way that allows for scalability and better supply chain management.